Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Bought by Marquette Asset Management LLC

Marquette Asset Management LLC grew its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNYGet Rating) by 7.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 38,000 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Marquette Asset Management LLC owned 0.07% of Chinook Therapeutics worth $665,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Amalgamated Bank acquired a new position in shares of Chinook Therapeutics during the 1st quarter valued at $77,000. International Biotechnology Trust PLC increased its position in shares of Chinook Therapeutics by 17.6% during the 1st quarter. International Biotechnology Trust PLC now owns 340,389 shares of the company’s stock valued at $4,714,000 after purchasing an additional 51,000 shares during the period. Great Point Partners LLC increased its position in shares of Chinook Therapeutics by 265.0% during the 1st quarter. Great Point Partners LLC now owns 1,423,682 shares of the company’s stock valued at $23,291,000 after purchasing an additional 1,033,641 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Chinook Therapeutics by 7.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 234,738 shares of the company’s stock worth $3,841,000 after acquiring an additional 16,512 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Chinook Therapeutics in the 1st quarter worth $760,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KDNY. Stifel Nicolaus began coverage on Chinook Therapeutics in a report on Monday, June 27th. They issued a “buy” rating and a $30.00 target price on the stock. HC Wainwright lifted their target price on Chinook Therapeutics from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, August 15th.

Insider Transactions at Chinook Therapeutics

In other news, insider Andrew James King sold 5,000 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $18.09, for a total value of $90,450.00. Following the completion of the sale, the insider now owns 5,897 shares of the company’s stock, valued at $106,676.73. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 23.38% of the stock is currently owned by insiders.

Chinook Therapeutics Stock Performance

Shares of Chinook Therapeutics stock traded down $0.67 during midday trading on Friday, hitting $18.99. The company’s stock had a trading volume of 577,271 shares, compared to its average volume of 515,776. The stock has a 50-day simple moving average of $20.48 and a 200-day simple moving average of $17.39. Chinook Therapeutics, Inc. has a 1-year low of $10.48 and a 1-year high of $23.86.

Chinook Therapeutics (NASDAQ:KDNYGet Rating) last issued its earnings results on Monday, August 8th. The company reported ($0.61) EPS for the quarter, hitting the consensus estimate of ($0.61). Chinook Therapeutics had a negative return on equity of 22.18% and a negative net margin of 170.15%. On average, sell-side analysts anticipate that Chinook Therapeutics, Inc. will post -2.47 EPS for the current fiscal year.

About Chinook Therapeutics

(Get Rating)

Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

Further Reading

Want to see what other hedge funds are holding KDNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chinook Therapeutics, Inc. (NASDAQ:KDNYGet Rating).

Institutional Ownership by Quarter for Chinook Therapeutics (NASDAQ:KDNY)

Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.